Taysha Gene Therapies, Inc. (TSHA)
Nasdaq · Healthcare · Biotechnology
$4.49−3.02%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.5B
- 52-week range
- $3.69 – $7.30
- 52-week change
- −1.91%
- EPS (trailing)
- −$0.41
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $9.8M (+17.28%)
- Net income
- −$109M
- Operating margin
- −1130.7%
- Diluted EPS
- −$0.34
- Free cash flow
- −$93.8M
From the company’s annual report on SEC EDGAR.
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Headquarters: Dallas, United States · 99 employees · tayshagtx.com